Insulinoma: analysis of prevalence and incidence in the world

BACKGROUND : Currently, there are no data on the prevalence and incidence of insulinoma in Russia. The published world data on the epidemiology of the tumor are largely variable. Thus, it is important to systematize information on the prevalence and incidence of insulinoma in the world, including in Russia. AIM: To assess the prevalence and incidence of insulinoma in the world. TASKS Analysis of literature data. Analysis of the database of the Endocrinology Research Centre. MATERIALS AND METHODS : To implement Task 1, an analysis of foreign and Russian articles published in the PubMed and eLIBRARY.RU databases from 1927 was carried out until June 1, 2023, including the following keywords: «Insulinoma», «Epidemiology», «Frequency», «Incidence», «Nationwide», «Database». Based on the obtained results, an analysis of the prevalence and incidence of insulinoma in the world and in Russia was made. To implement Task 2, the analysis of patient records and the electronic database of the Endocrinology Research Centre was carried out. RESULTS : Based on data in individual countries the prevalence and incidence of insulinoma for the world population amounted to: an average of 16.4 per 1 million population and 0.9 per 1 million population per year, respectively. If extrapolating the world data, the number of patients with insulinoma in Russia can be 1066–2362 and 72–173 new cases are diagnosed annually (11.9 per 1 million population and 0.9 per 1 million population per year, respectively). The largest number of patients with insulinoma in Russia was recorded in the Endocrinology Research Centre and amounted to 275 cases for the period 2006–2022. CONCLUSION: In the Russian Federation, it is important to create a register of patients with insulinoma on the basis of the existing electronic database of the Endocrinology Research Centre in order to obtain accurate information about the current needs of patients with insulinoma in medical care and drug provision, as well as to conduct full-fledged scientific research.